Executive summary

Pharma exports 2025
USD 10.4bn
+11.8% YoY; bio = 62.6%
KPBMA 2026
Songdo bioreactor base
785kL
Samsung Biologics alone, Plants 1-5
SBL FY25
US FDA biosimilars '25
5 of 18
Korea = most of any country
MDToday 2026
CDMO + biosimilar rev
USD ~6bn
SBL + Celltrion + SBE FY25
Kira est.

The market is small; the export lever is not

Domestic pharma is a slow-growing base near USD 23 bn in 2025 on a ~2.4% trajectory [Korea Pharma Outlook 2025]. The story sits in exports: medicine exports reached USD 10.4 bn in 2025, up 11.8%, with biologics at 62.6% of the total [KPBMA 2026]. Korea sells capacity and molecules, not its home market.

Two engines, compounding

Biosimilars give Korea a pipeline edge — 5 of 18 US FDA biosimilar approvals in 2025, the most of any country, led by Celltrion and Samsung Bioepis [MDToday 2026]. CDMO gives it scale: Samsung Biologics cleared KRW 4.56 trn revenue and KRW 6 trn in new orders in 2025 [SBL FY25]. The BIOSECURE Act, signed into the FY26 NDAA, hands Korean plants the demand Chinese CDMOs vacate [Lawtimes 2026].

Korea medicine exports & bio share
USD bn · 2021-2027F
USD BN
SOURCE: KPBMA, KOREA CUSTOMS · FORECAST = KIRA TRIANGULATION · KIRA RESEARCH 2026
KPBMA 2026 = Korea Pharmaceutical & Bio-Pharma Manufacturers Assoc. export data 2025 · MDToday 2026 = MDToday FDA biosimilar approval tally 2026 · SBL FY25 = Samsung Biologics FY2025 results · Korea Pharma Outlook 2025 = industry market-size compilation 2025 · Lawtimes 2026 = legal analysis of BIOSECURE Act 2026 · Kira estimates = KIRA in-house analyst triangulation

Market size & the export mix: where the growth actually sits

The domestic market is a stable, demographically-driven base. The expansion vector is the bio-export lever — biosimilars plus contract manufacturing — which is where capacity and pipeline decisions earn their return.

Domestic: slow, aging, defensive

Korea's domestic pharma market sits near USD 23 bn in 2025, growing about 2.4% a year toward USD 26 bn by 2030 [Korea Pharma Outlook 2025]. An aging population and broad national insurance support volume, but price control and tendering cap value growth. Oncology and large-molecule biologics are the fastest domestic segments.

Exports: the real engine

Medicine exports hit USD 10.4 bn in 2025, up 11.8%, with biologics at 62.6% of the total [KPBMA 2026]. The mix has shifted hard toward biosimilars and CDMO output. First-half 2025 health exports — pharma, biosimilars, diagnostics — passed USD 13 bn, a fresh record [Korea Health Export 2025].

Innovation, not just volume

In 2025 Korean firms signed technology-transfer deals worth over USD 4.8 bn [Korea Health Export 2025]. Korea increasingly exports the right to make molecules, not only the molecules — a higher-margin layer on top of product shipments.

Domestic market vs bio exports
USD bn · 2023-2030F
USD BN
SOURCE: KPBMA, KOREA CUSTOMS, MARKET COMPILATIONS · FORECAST = KIRA TRIANGULATION · KIRA RESEARCH 2026
KPBMA 2026 = Korea Pharmaceutical & Bio-Pharma Manufacturers Assoc. export data 2025 · Korea Pharma Outlook 2025 = industry market-size compilation 2025 · Korea Health Export 2025 = Korea health-sector export review H1 2025 · Kira estimates = KIRA in-house analyst triangulation